Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Degenerative Disc Disease ll: Pathophysiology01:23

Degenerative Disc Disease ll: Pathophysiology

The symptoms of degenerative disc disease arise from a combination of mechanical compression, vascular compromise, and biochemical inflammation, which together disrupt nerve function and produce pain.Mechanical CompressionDisc degeneration reduces height and elasticity, predisposing to herniation of the nucleus pulposus, a major cause of radicular pain. Herniations may be protrusion (bulging with intact annulus), extrusion (nucleus extends beyond disc but remains connected), or sequestration...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

β-Sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E mice.

Gene therapy·2015
Same author

AAV1.NT-3 gene therapy attenuates spontaneous autoimmune peripheral polyneuropathy.

Gene therapy·2015
Same author

The 2-min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositis.

Neuromuscular disorders : NMD·2013
Same author

Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery.

Molecular therapy : the journal of the American Society of Gene Therapy·2013
Same author

Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D.

Neurology·2008
Same author

Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.

Neurology·2007
Same journal

Dupilumab Emerges as an Effective Antibody Therapy for Eosinophilic Esophagitis.

Annual review of medicine·2026
Same journal

CAR T Cell Toxicities and Emerging Treatment Strategies.

Annual review of medicine·2026
Same journal

Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

Annual review of medicine·2026
Same journal

Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

Annual review of medicine·2026
Same journal

Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

Annual review of medicine·2026
Same journal

Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

Annual review of medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 5, 2026

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

Chronic inflammatory demyelinating polyradiculoneuropathy

J R Mendell1

  • 1Department of Neurology, Ohio State University, Columbus 43210.

Annual Review of Medicine
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired condition causing progressive weakness and sensory loss. Treatment with immunosuppressants like prednisone and plasma exchange can improve outcomes for patients with this chronic or relapsing condition.

More Related Videos

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
08:56

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies

Published on: October 7, 2021

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Related Experiment Videos

Last Updated: Jul 5, 2026

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
08:56

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies

Published on: October 7, 2021

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Area of Science:

  • Neurology
  • Immunology
  • Clinical Medicine

Background:

  • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired neurological disorder.
  • It is characterized by progressive, symmetrical weakness and sensory loss.
  • CIDP can follow a chronic or relapsing course, impacting patient mobility.

Purpose of the Study:

  • To describe the key features of CIDP.
  • To highlight diagnostic indicators.
  • To outline therapeutic responses.

Main Methods:

  • Clinical assessment of weakness and reflexes.
  • Electrophysiological nerve conduction studies.
  • Cerebrospinal fluid analysis and nerve biopsy.

Main Results:

  • Progressive symmetrical weakness (proximal and distal) and depressed reflexes.
  • Variable sensory loss; elevated cerebrospinal fluid protein without pleocytosis.
  • Nerve conduction studies and biopsy confirm demyelination.

Conclusions:

  • CIDP is a treatable demyelinating neuropathy.
  • Immunosuppressive therapies, including prednisone and plasmapheresis, are effective.
  • Early diagnosis and treatment are crucial for managing CIDP.